Gilbert, R., Bonilla, C., Metcalfe, C., Lewis, S., Evans, D. M., Fraser, W. D., ... Martin, R. M. (2015). Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case–control study. *Cancer Causes and Control, 26*(2), 205-218. https://doi.org/10.1007/s10552-014-0500-5
Associations of vitamin D pathway genes with circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D, and prostate cancer: a nested case–control study

Rebecca Gilbert · Carolina Bonilla · Chris Metcalfe · Sarah Lewis · David M. Evans · William D. Fraser · John P. Kemp · Jenny L. Donovan · Freddie C. Hamdy · David E. Neal · J. Athene Lane · George Davey Smith · Mark Lathrop · Richard M. Martin

Received: 2 July 2014 / Accepted: 13 November 2014 / Published online: 9 December 2014 © The Author(s) 2014. This article is published with open access at Springerlink.com

Abstract

Purpose Vitamin D pathway single nucleotide polymorphisms (SNPs) are potentially useful proxies for investigating whether circulating vitamin D metabolites [total 25-hydroxyvitamin-D, 25(OH)D; 1,25-dihydroxyvitamin, 1,25(OH)2D] are causally related to prostate cancer. We investigated associations of sixteen SNPs across seven genes with prostate-specific antigen-detected prostate cancer.

Methods In a nested case–control study (within the ProtecT trial), we estimated odds ratios and 95 % confidence intervals (CIs) quantifying associations between SNPs and prostate cancer. Subgroup analyses investigated whether associations were stronger in men who had high/low sun exposure [a proxy for 25(OH)D]. We quantified associations of SNPs with stage (T1–T2/T3–T4) and grade (<7/≥7). Multiple variant scores included SNPs encoding proteins involved in 25(OH)D synthesis and metabolism.

Results We included 1,275 prostate cancer cases (141 locally advanced, 385 high grades) and 2,062 healthy controls. Vitamin D-binding protein SNPs were associated with prostate cancer (rs4588-A: OR 1.20, CI 1.01, 1.41, \(p=0.04\); rs7041-T: OR 1.19, CI 1.02, 1.38, \(p=0.03\)). Low 25(OH)D metabolism score was associated with high (vs low) grade (OR 0.76, CI 0.63, 0.93, \(p=0.01\)); there was a similar association of its component variants: rs6013897-A in CYP24A1 (OR 0.78, CI 0.60, 1.01, \(p=0.06\)) and rs10877012-T in CYP27B1 (OR 0.80, CI 0.63, 1.02, \(p=0.07\)). There was no evidence that associations differed by level of sun exposure.

Electronic supplementary material The online version of this article (doi:10.1007/s10552-014-0500-5) contains supplementary material, which is available to authorized users.
Conclusion We found some evidence that vitamin D pathway SNPs were associated with prostate cancer risk and grade, but not stage. There was no evidence of an association in men with deficient vitamin D (measured by having low sun exposure).

Keywords Prostate cancer · Vitamin D · Vitamin D pathway genes · 25 hydroxyvitamin-D · 1,25-dihydroxyvitamin-D

Introduction Prostate cancer is the most common male cancer in industrialized countries but knowledge of modifiable risk factors is limited. Metabolites of vitamin D [total 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin, 1,25(OH)D] is limited. Metabolites of vitamin D metabolism and signalling could lend support to the hypothesis that vitamin D is related to prostate cancer and that the association is stronger in men who have a low level of sun exposure (as a proxy for deficient vitamin D status). We hypothesized that polymorphisms that reflect lower levels or cellular uptake of vitamin D could have an influence on cancer, including prostate cancer, despite not being associated with circulating vitamin D levels in previous studies, but we include these SNPs in our analysis as components of the vitamin D pathway that could have an influence on cancer, including prostate cancer, an important factor in the PSA-era due to the increasingly earlier detection of localized disease. We hypothesized that polymorphisms that reflect lower levels or cellular uptake of total 25(OH)D or 1,25(OH)2D are associated with prostate cancer risk [8-10]. In line with some other studies [10, 11], recent results from the cohort reported in this paper found a two-fold increased risk of more aggressive (locally advanced stage and/or high grade) prostate cancers in men with deficient (vs adequate) circulating 25(OH)D [11], but no association of 1,25(OH)2D with prostate cancer risk, stage, or grade [12].

In Mendelian randomization analyses, genetic variants can be used as proxy measures of nutritional exposure to determine the unconfounded and unbiased effect of modifiable risk factors on disease outcomes which are not subject to the biases commonly found in observational studies (e.g., reverse causation, recall bias, confounding) [13, 14]. SNPs that are located in genes related to vitamin D metabolism and signalling could lend support to the hypothesis that vitamin D is related to prostate cancer and thus improve the case for a causal relationship. Several genetic variants regulate or influence the levels or actions of our exposure of interest [circulating 25(OH)D and 1,25(OH)2D]. Thus, if the intermediate phenotype is causally associated with the outcome (prostate cancer) then we would expect the genetic variants to be associated with the outcome, to the extent that the genetic variants affect the intermediate phenotype. There are a number of single nucleotide polymorphisms (SNPs) involved in the vitamin D pathway which are potentially useful proxies for investigating whether circulating vitamin D is causally related to prostate cancer: vitamin D 25-hydroxylase enzyme (CYP2R1) converts provitamin D (from sun exposure or dietary intake) into circulating 25(OH)D [15]; 1-x-hydroxylase (CYP27B1) converts 25(OH)D into 1,25(OH)2D (the active form of the hormone) [16]; circulating 1,25(OH)2D is degraded by 24-hydroxylase (CYP24A1) [16] to 24,25(OH)2D; vitamin D-binding protein (VDBP or GC) is the major carrier of 25(OH)D and 1,25(OH)2D, transporting the metabolites to the target tissue [17]; and the vitamin D-receptor gene (VDR) is a key mediator of the biological actions of 1,25(OH)2D [2]. VDR SNPs have not been found to be associated with circulating vitamin D levels in previous studies, but we include these SNPs in our analysis as components of the vitamin D pathway that could have an influence on cancer, including prostate cancer, despite not being associated with circulating vitamin D levels [18]. Recent genome-wide association studies (GWAS) have uncovered robust associations of 25(OH)D concentration with polymorphisms in the genetic variants in VDBP, CYP2R1, CYP24A1, and a region on chromosome 11 encompassing the genes for the 7-dehydrocholesterol reductase (DHCR7) and NAD synthetase 1 (NADSYN1) [19, 20]. Within this region, DHCR7 is the most obvious candidate encoding an enzyme that catalyzes the conversion of 7-dehydrocholesterol (a precursor of vitamin D) to cholesterol.

We investigated associations of vitamin D pathway polymorphisms with PSA-detected prostate cancer, overall and stratified by stage and grade, in a large UK-wide population-based case-control study [21]. Few studies involve exclusively PSA-detected prostate cancer, an important factor in the PSA-era due to the increasingly earlier detection of localized disease. We hypothesized that polymorphisms that reflect lower levels or cellular uptake of total 25(OH)D or 1,25(OH)2D are associated with an increased risk of prostate cancer and that the association is stronger for locally advanced versus localized, and high-grade versus low-grade cancer. Given previous reports [10, 11, 22-24], we also investigated the possibility of a gene-environment interaction, i.e., whether the association is stronger in men who have a low level of sun exposure (as a proxy for deficient vitamin D status). We hypothesized that, among men with deficient vitamin D levels, those who have a genotype which improves cellular vitamin D status would have a lower risk of prostate cancer than men without this genotype, whereas this association would not be as strong in men with sufficient levels.
Materials and methods

Participants

The study is nested within a multi-center randomized controlled trial of treatments for localized disease: the Prostate Testing for cancer and Treatment (ProtecT) study [11, 21]. During recruitment to the ProtecT study (between 2001 and 2009), over 100,000 men aged 50–69 years at 337 general practices in nine UK centers (Birmingham, Bristol, Cambridge, Cardiff, Edinburgh, Leeds, Leicester, Newcastle, Sheffield) were offered a PSA test at a community-based ‘prostate check clinic’, and those with raised levels (≥3 ng/mL) were offered diagnostic biopsy. Detected tumors were all histologically confirmed and clinically staged using the TNM system [25]. Cancer stages T1–T2 were categorized as ‘localized’ and T3–T4 as ‘locally advanced’ as there were very few T4/metastatic tumors. ‘High-grade’ tumors were defined as a Gleason score ≥7 and low-grade tumors as Gleason score <7, after review of biopsy cores by a specialist uropathologist.

Case–control selection

A total of 1,914 cases and 48,692 controls were potentially eligible for selection for the current study (based on men recruited between 2003 and 2008), had provided a plasma sample, and consented to prostate cancer research. We randomly selected one stratum-matched control for each case from those men who had provided a non-fasted blood sample at the prostate check clinic. Controls were randomly selected from the same stratum—i.e., 5-year age band (age at PSA test) and GP/family practice—as cases. Prostate check clinics were held over consecutive weeks at each GP practice, and so matching cases and controls by band (age at PSA test) and GP/family practice—as cases. Controls were randomly selected from the same stratum—i.e., 5-year age band (age at PSA test) and GP/family practice—as cases. Prostate check clinics were held over consecutive weeks at each GP practice, and so matching cases and controls by GP also matches on time and season of blood draw. All participants in the ProtecT prostate check clinics who had no evidence of prostate cancer were eligible for selection as controls; that is, men with a PSA test <3 ng/mL, or a raised PSA (≥3 ng/mL) combined with at least one negative biopsy and no subsequent prostate cancer diagnosis during the follow-up protocol for negative biopsies. All men provided written informed consent prior to inclusion in the study. Trent Multicentre Research Ethics Committee (MREC) approved the ProtecT study (MREC/01/4/025) and the associated ProMPT study which collected biological material (MREC/01/4/061).

Vitamin D pathway genes and vitamin D assays

The following genes were genotyped in ProtecT participants as part of a genetic association study examining the effect of 70 diet/nutrition relevant SNPs on prostate cancer risk [18, 26]: VDR (ApaI: rs7975232, BsmI: rs1544410, FokI: rs10735810, TaqI: rs731236, Cdx2: rs11568820); VDBP (rs4588, rs7041); and CYP27B1 (rs10877012). DNA extraction was performed by Tepnel (http://www.tepnel.com, and genotyping was undertaken by KBioscience Ltd (www.kbioscience.co.uk), who use their own form of competitive allele-specific PCR (KASPar) and Taqman™ for SNP analysis. Samples with more than 10% genotype failure (7 SNPs) were defined as having poor DNA quality (2.6%) and dropped from further analysis. Genotyping was repeated in 10% of the study samples (with independent assessment) and for 99.98% of those samples there was exact agreement between the two.

The remaining vitamin D pathway SNPs (CYP2R1: rs10741657, rs2060793; CYP24A1: rs6013897; DHCR7: rs12785878; NADSYN1: rs3829251; VDBP: rs2282679, rs1155563; CYP27B1: rs703842) were obtained from genome-wide genotyping of ProtecT samples, carried out on 3,390 individuals [27] at the Center National de Génotypage (Evry, France), using the Illumina Human660W-Quad_v1_A array (Illumina Inc.). The quality control process done before imputation excluded individuals on the basis of the following: sex mismatches, minimal (≤0.325) or excessive heterozygosity (>0.345), disproportionate levels of individual missingness (>3%), cryptic relatedness measured as proportion of identity by descent (IBD > 0.1), and insufficient sample replication (IBD < 0.8). The remaining individuals were assessed for evidence of population stratification by multidimensional scaling analysis and compared with HapMap II (release 22) European descent (CEU), Han Chinese (CHB), Japanese (JPT), and Yoruba (YRI) reference populations; all individuals with non-European ancestry were removed. SNPs with a minor allele frequency below 1%, a call rate of <95% or evidence for violations of Hardy–Weinberg equilibrium (p < 5 x 10^-7), were discarded.

Circulating concentrations of total 25(OH)D (ng/mL) and 1,25(OH)2D (pg/mL) were measured in blood plasma collected at the prostate check clinic, prior to diagnosis, as described previously [11, 28]. Briefly, 25(OH)D2 and 25(OH)D3 samples were measured using tandem mass spectrometry, in 31 batches over a period of approximately 3 months [11], and 1,25(OH)2D samples were quantified by immunoassay [28] over a 2 months period using a single batch of reagents. Vitamin D levels were measured blind to diagnosis. Circulating concentrations of 25(OH)D2 and 25(OH)D3 were measured in nanograms per milliliter (ng/mL) where 1 ng/mL = 2.5 nmol/L (nanomoles per liter), and 1,25(OH)2D was measured in picomoles per liter (pmol/L) where 1 pmol/L = 2.6 pmol/L. Total 25(OH)D (ng/mL) was calculated as the summation of 25(OH)D2 and 25(OH)D3.
Vitamin D pathway scores

Multiple variant allele scores were created based on SNPs found to be associated with vitamin D status in prior studies [29] and in the current study [30]. Two scores were calculated by summing up all appropriate SNPs in each individual: (1) Synthesis score: genes encoding proteins involved in 25(OH)D synthesis (CYP2R1 rs10741657, DHCR7 rs12785878) [29]; and (2) Metabolism score: genes encoding proteins involved in 25(OH)D metabolism (CYP24A1 rs6013897, CYP27B1 rs10877012) [29]. Each SNP genotype was coded as 0, 1, or 2 depending on the number of risk alleles the individual carries and their effects on vitamin D levels calculated so that an increasing score indicates decreasing levels of vitamin D. If there were missing SNP data, the individual was given a missing score.

Covariates

Measures of height, weight, weekly exercise, smoking status, family history of prostate cancer, history of benign prostatic hyperplasia, diabetes, occupational social class, and self-reported ethnicity were collected at the time of the initial PSA test [31], prior to knowledge of the PSA level or diagnosis in 85% of men. We calculated body mass index (BMI; kg/m²), which represents general adiposity. A measure of ‘intense sun exposure’ was derived by summing time spent sunbathing, on holiday, and in foreign countries, from birth up until 2 years prior to the prostate clinic [8]. Missing answers were considered as zero; however, scores were not calculated if more than half of answers were missing. These sun exposure questions have been analyzed in detail previously, and further details of their derivation are published [8].

To avoid bias caused by complete case analysis [32], we multiply imputed all missing covariate values (i = 10) using chained equations [33], assuming those values could be predicted without bias from the observed relationships between covariates and the outcome measure, and substituting imputed values for missing values. The proportion of missing values per covariate was: age-group 0%, ethnicity 0.3%, BMI 28%, smoking 26%, family history of prostate cancer 11%, history of BPH 2%, diabetes 30%, social class 6%, and intense sun exposure 48%.

Statistical analysis

Vitamin D pathway SNPs and scores and circulating 25(OH)D and 1,25(OH)2D

Genotypes were checked for deviation from Hardy–Weinberg equilibrium using the hwsnp function implemented in Stata (Stata Corporation, College Station, Texas). Linear regression was used to examine the association of 25(OH)D and 1,25(OH)2D with individual SNPs and genetic scores, assuming an additive genetic model. Analyses were adjusted by age, study center, and season of blood draw.

Vitamin D pathway SNPs and scores and prostate cancer risk

To allow for the matched sets of cases and controls, conditional logistic regression was used to estimate odds ratios (OR) and 95% confidence intervals (CIs) quantifying the association between exposure and all prostate cancers. The model included the case–control matching variables, age, and GP/family practice. A case-only analysis used unconditional logistic regression, controlling for age, study center, and season of blood draw (i.e., to reflect the matching variables), to quantify associations of SNPs with prostate cancer stage (locally advanced vs localized) and grade [high (≥7) vs low (<7)]. A case-only analysis was used as all cases have undergone biopsy, therefore removing potential detection bias which could otherwise occur through misclassification of control status because of imperfect sensitivity of the PSA test [34]. SNPs were included as single variants, and effects were estimated per change in allele.

Gene–environment interaction of SNPs and scores and levels on prostate cancer

The association of SNPs with prostate cancer was repeated, stratified by level of sun exposure. Since serum vitamin D level is an effect common to vitamin D pathway SNPs and confounders, attempting to estimate this association using serum vitamin D levels would have resulted in biased estimates which may have led to spurious associations between SNPs and prostate cancer risk (this is known as collider bias [35], Fig. 1). Instead, we used sun exposure as a proxy for high or low vitamin D level due to environmental factors, assuming that men with low sun exposure will tend to have lower vitamin D levels and that sun exposure was not associated with vitamin D pathway SNPs. The association of sun exposure with serum vitamin D level and SNPs were tested using t tests and Chi-squared tests, respectively.

A likelihood ratio test, comparing the main effects model with the model including an interaction term between the SNP and level of sun exposure, was used to calculate a p value for interaction. A dichotomized indicator of sun exposure was created based on levels above and below the median level of sun exposure.
Population stratification

The top 10 principal components (PCs) that reflect the population’s genetic structure were estimated according to Price et al. [36] from genome-wide SNPs genotyped, imputed and cleaned as described above. All 10 PCs were included as covariates in all regression models to account for confounding by population stratification.

All analyses were carried out in Stata 12 (StataCorp, 2012. College Station, TX). We used ice for multiple imputation with chained equations [33] for imputing missing data. All tests of statistical significance were two-sided.

Results

Characteristics of study participants

The current analysis includes 1,275 prostate cancer cases [1,131 (88.7 %) localized, 141 (11.1 %) locally advanced, 3 (0.24 %) missing stage; 887 (69.6 %) low grade, 385 (30.2 %) high grade, 3 (0.24 %) missing grade], and 2,062 controls that have at least one available SNP. 39.3 % of participants had data available on all SNPs, and 43 % were missing data on three or fewer SNPs. No man was missing more than 10 SNPs. Of these, 926 cases and 872 controls had an available 25(OH)D measurement and 779 cases and 737 controls had an available 1,25(OH)2D measurement (Fig. 2). The mean age of cases was 62.6 years and of controls was 61.7 years. As expected, the mean PSA level in cases was higher than in controls (9.5 vs 1.0 ng/mL).

There were no substantial differences in baseline characteristics between cases and controls, except that more cases had a family history of prostate cancer versus controls (8.2 vs 5.6 %) and more cases had a normal (18.5–25) BMI (30.1 vs 25.5 %). Of the 99.3 % of subjects, who had recorded ethnicity, 98.9 % self-identified as white.

The mean (SD) 25(OH)D concentration in cases was 23.7 ng mL (8.7) and in controls was 23.5 ng/mL (8.7) (p for difference = 0.62). The mean (SD) 1,25(OH)2D concentration in cases was 40.6 pg.mL (18.4) and in controls was 40.9 pg/mL (18.1) (p for difference = 0.74). There were no differences between mean storage times of blood samples between cases and controls. Only VDR SNP rs7975232 was out of Hardy–Weinberg equilibrium in controls (p = 0.01).

Vitamin D pathway SNPs and covariates

For the most part, there was no evidence of associations between vitamin D pathway SNPS and the covariates (data not shown). There was evidence of an association of VDBP rs4588-A with BMI (p = 0.01), CYP27B1 rs703842-G with smoking status (p = 0.02), diabetes (p = 0.01) and social class (p = 0.01) and CY27B1 rs10877012-T with smoking status (p = 0.01), and diabetes (p = 0.01). These
associations are possibly due to chance as we carried out multiple tests, i.e., we tested 16 SNPs against eight covariates.

Vitamin D pathway SNPs and circulating 25OHD and 1,25(OH)2D

There were up to 1,778 individuals with genome-wide SNP data and 25(OH)D and 1,25(OH)2D measurements. Of the 16 SNPs investigated, two SNPs in CYP2R1 (rs10741657-A, rs2060793-A) and two SNPs in VDR (Fokl-A, Taql-C) were associated with 25(OH)D concentrations (with ss ranging from ≤0.001 to 0.04) (Table 1). One SNP in DHCR7 (rs12785878-G) and four SNPs in VDR (Apal-C, Bsml-A, Taql-C, Cdxl-A) were associated with 1,25(OH)2D concentrations (with p values ranging from 0.01 to 0.04) (Table 1). Four SNPs in VDBP (rs2282679-G, rs4588-A, rs7041-T, rs1155563-C) were associated with both 25(OH)D and 1,25(OH)2D concentrations (all p values ≤0.01) (Table 1). The above analyses were limited to controls only and were adjusted for age, study center, season of blood draw, and PCs. Nevertheless, associations of SNPs with 25(OH)D and 1,25(OH)2D concentrations did not differ by case–control status (results not shown). Based on the proportion of trait variability explained and on the F-statistic, which is related to the strength of the instrument, the best instruments for 25(OH)D concentrations in this population were VDBP SNPs (F = 12.2–22.3). Strong associations were detected between all VDBP SNPs and 1,25(OH)2D (F = 5.88–9.62). However, each polymorphism explained only ~1 % of the trait variance, and the F-statistics were below 10, the conventional lower limit of a strong instrument [30].

Vitamin D pathway SNPs and prostate cancer risk

There was evidence of an association of linked VDBP SNPs rs4588-A and rs7041-T, representing low levels of 25(OH)D, with prostate cancer risk (rs4588: OR 1.20, 95 % CI 1.01, 1.41, p = 0.04; rs7041: OR 1.19, 95 % CI 1.02, 1.38, p = 0.03). There was no evidence that the other SNPs or scores were associated with prostate cancer risk (Table 2).

There was no convincing evidence that either the vitamin D pathway SNPs or the two scores were associated with stage (Table 3). There was evidence that the metabolism score, indicating decreasing 25(OH)D levels, was associated with Gleason grade (high vs low) (OR 0.76, 95 % CI 0.63, 0.93, p = 0.01), and marginal evidence for a similar association of its component variants rs6013897-A in CYP24A1 (OR 0.78, 95 % CI 0.60, 1.01, p = 0.06) and rs10877012-T in CYP27B1 (OR 0.80, 95 % CI 0.63, 1.02, p = 0.07) (representing low levels of 25(OH)D).

Vitamin D pathway SNPs, sun exposure and prostate cancer risk

The mean 25(OH)D level in men who had below the median sun exposure was 22.1 ng/mL and who had above the median sun exposure was 24.6 ng/mL (p for difference <0.001). None of the vitamin D pathway SNPs were associated with sun exposure (data available on request). There was no evidence of an association between any SNPs or scores and prostate cancer risk within men with below the median sun exposure (all p interaction >0.04) (Table 4).

Population stratification

All analyses were adjusted for population stratification. There was no evidence of an association between each SNP and score with the principal components used in this adjustment, indicating that population stratification was not likely to have affected our results (Supplementary Table 1).

Discussion

This study, of 1,275 prostate cancer cases and 2,062 healthy controls from the ProtecT study, investigated associations of sixteen vitamin D pathway polymorphisms with PSA-detected prostate cancer risk and, in cases, with stage and Gleason grade. There was evidence that two SNPs in VDBP, representing low 25(OH)D levels, were associated with increased prostate cancer risk and that a score measuring metabolism (indicating low 25(OH)D levels) and its component variants were associated with high Gleason grade. There was no other convincing evidence that vitamin D pathway SNPs were associated with prostate cancer risk, stage, or grade. There was no evidence that associations differed by level of sun exposure.

We validated the use of GWAS-identified SNPs in ProtecT as proxies for serum 25(OH)D as well as of scores including these variants, confirming associations reported in previous studies. The synthesis score appeared to be a reasonably strong instrument, although the scores explained less than 1 % of the trait variance for circulating 25(OH)D and 1,25(OH)2D. Four SNPs in VDBP (rs2282679, rs4588, rs7041, rs1155563) were strong instruments for 25(OH)D, and one SNP in VDBP (rs1155563) was a strong instrument for 1,25(OH)2D (those SNPs with F ≥ 10), explaining approximately 2 % of the variability.

Results from the Health Professionals Follow-up Study (HPFS) found that variants in CYP27A1 (p = 0.02) and VDR (12 SNPs, p = 0.01), and a score made up of seven
Table 1 The effects of vitamin D pathway SNPs on 25(OH)D (ng/mL) and 1,25(OH)\(_2\)D (pg/mL) concentrations in control subjects

| Polymorphism     | Chromosome | Major/Minor allele | MAF  | Effect of minor allele on 25(OH)D (ng/mL)\(^a\) | 95 % CI        | p value | F-statistic\(^b\) | R\(^2\) (%) | Effect of minor allele on 1,25(OH)\(_2\)D (pg/mL)\(^a\) | 95 % CI        | p value | F-statistic\(^b\) | R\(^2\) (%) |
|------------------|------------|--------------------|------|-----------------------------------------------|----------------|---------|--------------------|-----------|------------------------------------------------|----------------|---------|--------------------|-----------|
| CYP2R1 rs10741657| 1p15.2     | G/A                | 0.43 | 0.92                                          | (0.02, 1.83)   | 0.04    | 697     | 4.71      | 0.70                                          | 0.16            | (-1.97, 2.28) | 0.09    | 592                | 0.03      | 0.00   |
| CYP2R1 rs2096793 | 1p15.2     | G/A                | 0.43 | 0.92                                          | (0.02, 1.83)   | 0.04    | 697     | 4.71      | 0.70                                          | 0.16            | (-1.97, 2.28) | 0.09    | 592                | 0.03      | 0.00   |
| DHCR7 rs12785878 | 1q13.4     | T/G                | 0.22 | 0.11                                          | (-1.05, 1.26)  | 0.06    | 697     | 0.02      | 0.00                                          | -3.85           | (-6.58, -1.12) | 0.01    | 592                | 0.58      | 1.00   |
| NADSYN1 rs3829251| 1q13.4     | G/T                | 0.13 | 0.29                                          | (-1.09, 1.68)  | 0.08    | 697     | 0.03      | 0.00                                          | -2.31           | (-5.59, 0.96) | 0.17    | 592                | 1.31      | 0.20   |

Synthesis score

| Topological score | High–low | -0.56 | (-1.28, 0.17) | 0.13 | 697 | 3.31 | 0.70 | -1.63 | (-3.35, 0.10) | 0.06 | 592 | 2.69 | 0.50 |

| VDBP rs2282679   | 4q12      | T/G    | 0.30 | -2.27 | (-3.23, -1.30) | <0.001 | 697 | 17.45 | 2.40 | -3.29 | (-5.61, -0.98) | 0.01 | 592 | 8.01 | 1.30 |

| VDBP rs4588      | 4q12      | C/A    | 0.29 | -2.14 | (-3.12, -1.17) | <0.001 | 687 | 22.26 | 2.50 | -3.17 | (-5.49, -0.85) | 0.01 | 584 | 8.17 | 1.10 |

| VDBP rs7041      | 4q12      | G/T    | 0.44 | -1.65 | (-2.53, -0.77) | <0.001 | 689 | 16.31 | 1.90 | -2.72 | (-4.82, -0.62) | 0.01 | 586 | 5.88 | 0.80 |

| VDBP rs1155563   | 4q12      | T/C    | 0.30 | -1.88 | (-2.85, -0.91) | <0.001 | 697 | 12.21 | 1.70 | -3.41 | (-5.71, -1.11) | 0.004 | 592 | 9.62 | 1.60 |

| CYP24A1 rs6013897| 20q13     | T/A    | 0.20 | -0.25 | (-1.37, 0.87)  | 0.67   | 697 | 0.18  | 0.00 | -1.62 | (-4.26, 1.03)  | 0.23 | 592 | 0.84 | 0.10 |

| CYP27B1 rs703842 | 12q13.1–13.3 | A/G | 0.33 | -0.06 | (-1.01, 0.89)  | 0.91   | 697 | 0.01  | 0.00 | -0.17 | (-2.38, 2.05)  | 0.88 | 592 | 0.00 | 0.00 |

| CYP27B1 rs10877012| 12q13.1–13.3 | G/T | 0.33 | 0.06 | (-0.91, 1.03)  | 0.90   | 675 | 0.00  | 0.00 | -0.20 | (-2.45, 2.04)  | 0.86 | 574 | 0.16 | 0.00 |

Metabolism score

| Metabolism score | High–low | -0.02 | (-0.78, 0.73) | 0.95 | 672 | 0.02 | 0.00 | -0.72 | (-2.49, 1.05) | 0.42 | 571 | 0.27 | 0.00 |

| VDR Aplai (rs7975232) | 12q13.11 | A/C | 0.48 | -0.46 | (-1.32, 0.40) | 0.29 | 681 | 0.88 | 0.10 | -2.39 | (-4.41, -0.38) | 0.02 | 580 | 4.79 | 0.70 |

| VDR BsmI (rs1544410) | 12q13.11 | G/A | 0.40 | 0.85 | (-0.06, 1.77) | 0.07 | 684 | 3.16 | 0.40 | 2.62 | (0.50, 4.75) | 0.02 | 580 | 3.85 | 0.50 |

| VDR FokI (rs10735812) | 12q13.11 | G/A | 0.38 | -1.26 | (-2.19, -0.32) | 0.01 | 688 | 6.30 | 0.70 | 0.88 | (-1.30, 3.06) | 0.43 | 584 | 0.57 | 0.10 |

| VDR TaqI (rs731236) | 12q13.11 | T/C | 0.40 | 0.98 | (0.06, 1.90)  | 0.04 | 691 | 3.85 | 0.40 | 2.26 | (0.13, 4.40) | 0.04 | 589 | 3.42 | 0.50 |

| VDR Cdx2 (rs11568820) | 12q13.11 | G/A | 0.21 | -0.33 | (-1.43, 0.76) | 0.55 | 689 | 0.86 | 0.10 | 3.73 | (1.12, 6.33) | 0.01 | 586 | 4.59 | 0.60 |

**MAF** minor allele frequency, **CI** confidence interval

\(^a\) Difference in mean levels, calculated using regression, adjusting for exact age, study center, season of blood draw and 10 principal components to account for confounding by population stratification

\(^b\) F-statistic and R-squared (R\(^2\)) indicate how much of the variability in vitamin D levels is explained by each SNP (i.e., the strength of each SNP as an instrument for vitamin D levels). F > 10 indicates a strong instrument. Calculated using regression, unadjusted

\(^c\) Synthesis score: rs10741657, rs12785878

\(^d\) Metabolism score: rs6013897, rs10877012
vitamin D pathway genes (CYP27A1, CYP2R1, CYP27B1, VDBP, CYP24A1, RXRA, VDR, \( p = 0.008 \)), were associated with risk of lethal prostate cancer [37]. There were no associations between prostate cancer risk and 212 SNPs from 12 genes related to vitamin D (including CYP27A1, VDBP, CYP27B1, CYP24A1, VDR) examined in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial (749 incident cases, 781 controls) [23]. Among men in the lowest tertile of 25(OH)D, there was an association between three VDR SNPs (rs11574143, rs757343, BsmI) and prostate cancer risk (the strongest association was for rs11574143: OR 2.49, 95 % CI 1.51, 4.11). Results from the National Cancer Institute Breast and Prostate Cancer Cohort Consortium (BPC3), a pooled analysis of 10,000 cases and 11,000 controls, found that genetic variants near CYP24A1 were associated with a decreased risk of aggressive prostate cancer (\( p \) trend <0.001), and a score made of four genes thought to predict circulating levels of 25(OH)D (VDBP, CYP24A1, CYP2R1, DHCR7) was related to both overall and aggressive prostate cancer [38]. There was no association between prostate cancer risk and the other SNPs. Variants in the VDR have been associated with advanced stage or high Gleason grade [18, 39], with a recent meta-analysis of 13 studies, including data from this study, finding an association between three VDR polymorphisms (Apal, BsmI and TaqI) and prostate cancer grade [18]. However, VDR SNPs have not been consistently associated with 25(OH)D or 1,25(OH)2D concentrations or with prostate cancer risk. A recent meta-analysis of 34 studies found no evidence of an association of VDR BsmI and FokI with prostate cancer risk [40]. VDR Cdx2 AA genotype was associated with prostate cancer in men with low 25(OH)D (\( \leq 15 \) ng/mL) (\( p \) interaction = 0.02) and with aggressive and high-grade prostate cancer in men with low 25(OH)D and 1,25(OH)2D (\( p \) interaction = 0.04 and 0.01, respectively) compared with men with normal levels [24]. Results from the Physician’s Health Study [22] found no associations of VDR BsmI or TaqI polymorphisms and prostate cancer risk (372 incident cases, 591 controls), although in men with 25(OH)D below the median there was a 57–62 % reduction in risk of men with the BsmI AA genotype (RR 0.43, 95 % CI 0.19, 0.98) or the TaqI CC genotype (data not shown) compared with men with the GG or TT genotypes. The risk was reduced by 80–90 % in men aged over 61 years (BsmI: RR 0.18, 95 % CI 0.05, 0.68). Variants in VDR, CYP24A1, and CYP27B1 were associated with progression to prostate cancer-specific mortality in a case-only study (\( n = 1.294 \)) [41]. Our recent study found no evidence that circulating levels or vitamin D pathway genes (VDR: Apal, BsmI, FokI, TaqI, Cdx2; VDBP: rs4588, rs7041; CYP27B1: rs10877012) influence PSA-defined progression in men with localized prostate cancer on active monitoring [42].

Our recent epidemiological study from the same cohort found a two-fold increased risk of more aggressive (locally advanced stage and/or high grade) prostate cancers in men deficient in circulating 25(OH)D (<12 ng/mL) [11]. However, none of the SNPs expected to modulate 25(OH)D were associated with prostate cancer risk, stage, or grade. SNPs in the VDR, a key mediator of the biological actions of 1,25(OH)2D [2], were not associated with stage or grade. Our recent study found no association between 1,25(OH)2D and prostate cancer risk, stage, or grade [12]. Circulating levels of 1,25(OH)2D are tightly regulated [1]. Biological evidence shows that the prostate can locally convert 25(OH)D to 1,25(OH)2D [43, 44], although prostate cancer tissue has a reduced ability to locally convert 25(OH)D to 1,25(OH)2D [45]. VDR is present in the prostate gland [43, 46], so VDR status may better indicate local 1,25(OH)2D status than circulating levels. Circulating levels may not be a good indicator of what is happening at the cellular level. Recent results from the Alpha-Tocopherol, Beta-carotene Cancer Prevention (ATBC), study found that their observed association between circulating vitamin D and prostate cancer risk was made stronger when vitamin D-binding protein concentrations were also elevated [47]. This suggests that VDBP may modulate the impact of vitamin D status on prostate cancer, even though the SNPs were not directly associated with prostate cancer risk overall. Two VDBP SNPs were associated with prostate cancer risk in the current study, although there was no evidence of an interaction when stratified by sun exposure (\( p \) interaction = 0.12).

Strength and limitations of our study

Our study includes a large sample, with more men with prostate cancer and matched controls than previous studies, about which we have extensive information recorded. All of our men were resident in the UK and 99 % of our subjects self-reported their ethnicity as white. Since the decision to biopsy was based on PSA level, some of the controls with PSA <3 ng/mL will have unidentified prostate cancer [34] (misclassification bias) but this would not affect our analysis of locally advanced versus localized cancers (as all cancers were biopsy confirmed). Any misclassification of cancer status is likely to be non-differential with respect to vitamin D pathway polymorphisms, at most moderately attenuating any effect-estimates [48]. Our case-only comparison uses 25OHD and 1,25(OH)2D concentrations measured in men diagnosed with locally advanced/high-grade cancer versus men diagnosed whilst their tumor was localized/low grade. We categorized cancer stages T3–T4 as ‘locally advanced’ as there were very few T4 metastasized tumors [~6 % have distal metastasis (T4 or M1)].
Table 2  Associations between vitamin D pathway SNPs and prostate cancer risk (cases vs controls)

| Polymorphism     | Major/minor allele | 25(OH)D-increasing allele\(^a\) | \(n\) (cases/controls) | Effect of minor allele\(^b\) |
|------------------|--------------------|---------------------------------|-----------------------|----------------------------|
| CYP2R1 rs10741657| G/A                | A                               | 349/637               | 1.00 (0.90, 1.13) 0.94     |
| CYP2R1 rs2060793 | G/A                | A                               | 349/637               | 1.00 (0.90, 1.13) 0.94     |
| DHCR7 rs12785878 | T/G                | T                               | 621/1177              | 1.07 (0.93, 1.23) 0.32     |
| NADSYN1 rs3829251| G/T                | A                               | 790/1418              | 0.97 (0.82, 1.15) 0.75     |
| Synthesis score\(^c\) | High–low           |                                 |                       |                           |
| VDBP rs2282679   | T/G                | T                               | 504/948               | 1.09 (0.96, 1.23) 0.17     |
| VDBP rs4588      | C/A                | C                               | 461/465               | 1.20 (1.01, 1.41) 0.04     |
| VDBP rs7041      | G/T                | G                               | 275/295               | 1.19 (1.02, 1.38) 0.03     |
| VDBP rs155563    | T/C                | T                               | 513/955               | 1.04 (0.92, 1.18) 0.52     |
| CYP24A1 rs6013897| T/A                | T                               | 665/1220              | 1.01 (0.87, 1.17) 0.92     |
| CYP27B1 rs703842 | A/G                | A                               | 456/866               | 1.06 (0.93, 1.19) 0.38     |
| CYP27B1 rs10877012| G/T               | G                               | 405/413               | 1.02 (0.86, 1.20) 0.85     |
| Metabolism score\(^d\) | High–low           |                                 |                       |                           |
| VDR Apal         | A/C                | A                               | 259/251               | 0.94 (0.81, 1.10) 0.45     |
| VDR BsmI         | G/A                | A                               | 342/334               | 1.07 (0.91, 1.25) 0.41     |
| VDR FokI         | G/A                | G                               | 353/339               | 1.06 (0.90, 1.25) 0.51     |
| VDR TaqI         | T/C                | C                               | 345/339               | 1.06 (0.91, 1.25) 0.45     |
| VDR Cdx2         | G/A                | G                               | 599/560               | 1.03 (0.86, 1.24) 0.72     |

OR odds ratio, CI confidence interval

\(^a\) Determined from ProtecT data (presented in Table 1)

\(^b\) Case versus control models are calculated using conditional logistic regression, stratum matched on 5 years age band and GP surgery. Models additionally included exact age and 10 principal components to account for confounding by population stratification

\(^c\) Synthesis score: rs10741657, rs12785878

\(^d\) Metabolism score: rs6013897, rs10877012
Table 3 Associations between vitamin D pathway SNPs and prostate cancer stage and Gleason grade (case-only analyses)

| Polymorphism | Major/Minor allele | Stage: advanced versus localized | 
|--------------|--------------------|----------------------------------|
|              | Major homozygote   | Heterozygote                     | Minor homozygote | Effect of minor allele: OR (95% CI) | p value |
|              |                    |                                 |                  |                                    |         |
| CYP2R1 rs10741657 | G/A                | A                                | 41/308           | 1.03 (0.78, 1.37)                  | 0.81     |
|              |                    |                                  | 48/436           |                                |         |
|              |                    |                                  | 24/180           |                                |         |
| CYP2R1 rs2060793 | G/A                | A                                | 41/308           | 1.03 (0.78, 1.37)                  | 0.81     |
|              |                    |                                  | 48/436           |                                |         |
|              |                    |                                  | 24/180           |                                |         |
| DHCR7 rs12785878 | T/G                | T                                | 70/550           | 0.95 (0.66, 1.35)                  | 0.76     |
|              |                    |                                  | 39/333           |                                |         |
|              |                    |                                  | 4/41             |                                |         |
| NADSyn1 rs3829251 | G/T                | A                                | 88/701           | 0.99 (0.64, 1.53)                  | 0.95     |
|              |                    |                                  | 23/210           |                                |         |
|              |                    |                                  | 2/13             |                                |         |
| Synthesis score | High–low           |                                  | 0.96             | (0.77, 1.19)                      | 0.71     |
|              |                    |                                  |                  |                                |         |
| VDBP rs2282679  | T/G                | T                                | 5/451            | 1.01 (0.74, 1.37)                  | 0.94     |
|              |                    |                                  | 49/383           |                                |         |
|              |                    |                                  | 11/88            |                                |         |
| VDBP rs4588    | C/A                | C                                | 45/416           | 1.17 (0.81, 1.69)                  | 0.41     |
|              |                    |                                  | 51/346           |                                |         |
|              |                    |                                  | 11/81            |                                |         |
| VDBP rs7041    | G/T                | G                                | 23/252           | 1.11 (0.78, 1.59)                  | 0.56     |
|              |                    |                                  | 57/413           |                                |         |
|              |                    |                                  | 23/178           |                                |         |
| VDBP rs1155563 | T/C                | T                                | 55/458           | 0.99 (0.73, 1.34)                  | 0.95     |
|              |                    |                                  | 46/374           |                                |         |
|              |                    |                                  | 12/92            |                                |         |
| CYP24A1 rs6013897 | T/A               | T                                | 75/590           | 1.04 (0.72, 1.51)                  | 0.82     |
|              |                    |                                  | 32/315           |                                |         |
|              |                    |                                  | 6/19             |                                |         |
| CYP2B1 rs703842 | A/G                | A                                | 53/403           | 0.91 (0.67, 1.24)                  | 0.56     |
|              |                    |                                  | 46/419           |                                |         |
|              |                    |                                  | 14/102           |                                |         |
| CYP2B1 rs1087701 | G/T                | G                                | 46/359           | 0.92 (0.63, 1.33)                  | 0.65     |
|              |                    |                                  | 46/360           |                                |         |
|              |                    |                                  | 11/99            |                                |         |
| Metabolism score | High–low         |                                  | 0.82             | (0.61, 1.10)                      | 0.18     |
|              |                    |                                  |                  |                                |         |
| VDR Apal      | A/C                | A                                | 31/237           | 1.12 (0.80, 1.59)                  | 0.51     |
|              |                    |                                  | 53/434           |                                |         |
|              |                    |                                  | 23/179           |                                |         |
| VDR BosmI     | G/A                | A                                | 37/304           | 1.04 (0.74, 1.47)                  | 0.82     |
|              |                    |                                  | 53/414           |                                |         |
|              |                    |                                  | 17/126           |                                |         |
| VDR FokI      | G/A                | G                                | 37/314           | 1.12 (0.78, 1.61)                  | 0.54     |
|              |                    |                                  | 54/431           |                                |         |
|              |                    |                                  | 15/96            |                                |         |
| VDR TaqI      | T/C                | C                                | 35/309           | 1.04 (0.74, 1.48)                  | 0.8      |
|              |                    |                                  | 55/409           |                                |         |
|              |                    |                                  | 17/126           |                                |         |
| VDR Cdx2      | G/A                | G                                | 57/539           | 1.30 (0.89, 1.89)                  | 0.18     |
|              |                    |                                  | 38/258           |                                |         |
|              |                    |                                  | 11/45            |                                |         |

Locally advanced stage is T3–T4, localized stage is T1–T2, N0, M0. High grade is Gleason grade ≥7, low grade is <7.

*OR* odds ratio, *CI* confidence interval

*Case-only models are calculated using logistic regression, adjusted for exact age, season of blood draw, and study center location. Models additionally included 10 principal components to account for confounding by population stratification.

*b* Determined from ProteCt data (presented in Table 1)

*c* Synthesis score: rs10741657, rs12785878

*d* Metabolism score: rs6013897, rs10877012
| Polymorphism | Major/minor allele | n (cases/controls) | Effect of minor allele<sup>a</sup> | n (cases/controls) | Effect of minor allele<sup>a</sup> | p interaction<sup>b</sup> | p interaction<sup>b</sup> |
|--------------|--------------------|-------------------|-------------------------------|-------------------|-------------------------------|-------------------|-------------------|
| CYP2R1 rs10741657 | G/A | 163/239 | 221/363 | 92/130 | 1.00 (0.84, 1.18) | 128/205 | 182/263 | 81/116 | 1.05 (0.87, 1.27) | 0.55 |
| CYP2R1 rs2060793 | G/A | 163/239 | 221/363 | 92/130 | 1.00 (0.84, 1.18) | 128/205 | 182/263 | 81/116 | 1.05 (0.87, 1.27) | 0.55 |
| DHCR7 rs12785878 | T/G | 279/461 | 173/226 | 24/45 | 1.07 (0.87, 1.31) | 233/363 | 143/196 | 15/25 | 0.99 (0.78, 1.26) | 0.47 |
| NADSYN1 rs3829251 | G/T | 352/558 | 118/161 | 6/13 | 1.06 (0.82, 1.36) | 303/445 | 81/128 | 7/11 | 0.87 (0.65, 1.16) | 0.28 |
| Synthesis score<sup>c</sup> | High–low | 1.03 (0.90, 1.18) | 0.97 (0.83, 1.12) | 0.14 |
| VDBP rs2282679 | T/G | 250/367 | 194/299 | 32/66 | 0.90 (0.75, 1.10) | 183/319 | 163/216 | 45/40 | 1.14 (0.93, 1.40) | 0.04 |
| VDBP rs8558 | C/A | 210/208 | 189/168 | 32/41 | 1.06 (0.81, 1.40) | 142/172 | 124/123 | 40/23 | 1.34 (1.10, 1.65) | 0.08 |
| VDBP rs7041 | G/T | 126/134 | 216/190 | 86/95 | 1.07 (0.84, 1.37) | 84/110 | 155/157 | 70/52 | 1.55 (1.15, 2.08) | 0.06 |
| VDBP rs1155563 | T/C | 250/370 | 187/297 | 39/65 | 0.92 (0.76, 1.11) | 192/315 | 159/213 | 40/56 | 1.66 (1.24, 2.22) | 0.26 |
| CYP24A1 rs6013897 | T/A | 311/483 | 153/221 | 12/28 | 0.93 (0.75, 1.16) | 242/379 | 138/188 | 11/17 | 1.15 (0.90, 1.49) | 0.52 |
| CYP27B1 rs703842 | A/G | 207/345 | 210/310 | 59/77 | 1.12 (0.93, 1.35) | 173/258 | 176/267 | 42/59 | 0.98 (0.80, 1.21) | 0.35 |
| CYP27B1 rs10877012 | G/T | 174/202 | 181/163 | 59/46 | 1.19 (0.93, 1.54) | 141/131 | 126/144 | 26/30 | 0.87 (0.64, 1.19) | 0.27 |
| Metabolism score<sup>d</sup> | High–low | 1.03 (0.85, 1.26) | 0.92 (0.73, 1.17) | 0.61 |
| VDR ApaI | A/C | 128/112 | 216/192 | 84/108 | 0.90 (0.71, 1.14) | 70/84 | 169/153 | 66/78 | 1.01 (0.76, 1.35) | 0.47 |
| VDR BsmI | G/A | 150/163 | 219/188 | 63/63 | 1.11 (0.87, 1.42) | 112/127 | 151/147 | 41/45 | 1.08 (0.79, 1.47) | 0.86 |
| VDR FokI | G/A | 172/152 | 209/188 | 47/72 | 0.91 (0.70, 1.18) | 103/127 | 159/153 | 46/40 | 1.34 (1.00, 1.78) | 0.24 |
| VDR TaqI | T/C | 150/167 | 214/192 | 64/59 | 1.10 (0.86, 1.41) | 115/128 | 154/151 | 40/43 | 1.04 (0.77, 1.42) | 0.83 |
| VDR Cdx2 | G/A | 271/265 | 135/134 | 24/18 | 1.08 (0.80, 1.45) | 189/187 | 95/108 | 17/18 | 0.78 (0.56, 1.07) | 0.46 |

OR odds ratio, CI confidence interval

<sup>a</sup>Case versus control models are calculated using conditional logistic regression, stratum matched on 5 years age band and GP surgery. Models additionally included exact age and 10 principal components to account for confounding by population stratification

<sup>b</sup>p for interaction calculated using a likelihood ratio test comparing the main effects model with the model including an interaction term between the SNP and an indicator of vitamin D deficiency

<sup>c</sup>Synthesis score: rs10741657, rs12785878

<sup>d</sup>Metabolism score: rs6013897, rs10877012
Circulating 25(OH)D and 1,25(OH)₂D concentrations were measured at one laboratory, in as few batches and in as short a time frame as possible (thus attenuating any potential technical errors of measurement). Circulating vitamin D levels were measured in plasma collected at the prostate check clinic prior to diagnosis, with measurement of vitamin D concentrations blind to diagnosis. The study is population-based and thus subject to little selection bias. Circulating levels of 25(OH)D may vary by season of tissue collection [49], which is not a problem when analyzing vitamin D pathway SNPs. It is possible that we are studying a relatively healthy population, within which there is not enough variation in vitamin D status to be able to detect an affect [25(OH)D: IQR in cases: 17.4,28.9 ng/mL; controls: 17.8,28.4 ng/mL; 1,25(OH)₂D: IQR in cases = 27.5,51.1 pg/mL; controls: 27.8,50.8]. Circulating 25(OH)D and 1,25(OH)₂D may not reflect the amount of vitamin D-binding protein were associated with prostate cancer risk (rs4588-A and rs7041-T). A score measuring metabolism, and its component variants (rs6013897-A in CYP24A1 and rs10877012T in CYP27B1), were associated with Gleason grade (high grade vs low grade). There was no association of other vitamin D pathway polymorphisms being associated with overall prostate cancer risk, stage, or grade. There was no evidence of an association in men with deficient vitamin D (measured by having low sun exposure).

Conclusion

Our study found evidence that two SNPs in vitamin D-binding protein were associated with prostate cancer risk (rs4588-A and rs7041-T). A score measuring metabolism, and its component variants (rs6013897-A in CYP24A1 and rs10877012T in CYP27B1), were associated with Gleason grade (high grade vs low grade). There was no association of other vitamin D pathway polymorphisms being associated with overall prostate cancer risk, stage, or grade. There was no evidence of an association in men with deficient vitamin D (measured by having low sun exposure).

Acknowledgments

Ethics approvals for ProtecT and ProMPT: All men provided written informed consent prior to inclusion in the study. Trent Multicentre Research Ethics Committee (MREC) approved the ProtecT study (MREC/01/4/025) and the associated ProMPT study which collected biological material (MREC/01/4/061). The authors would like to acknowledge the provision of additional epidemiological data by the NHS R&D Directorate supported Prolongal study. Also the ProMPT (Prostate Mechanisms of Progression and Treatment, Grant Code G0500966/75466) collaboration which has funded tissue and urine collections and is supported by the National Cancer Research Institute (NCRI) formed by the Department of Health, the Medical Research Council and Cancer Research UK. These collaborations are supported by the University of Cambridge Cancer Research UK, and the National Institute for Health Research funded Cambridge Bio-medical Research Center, Cambridge, UK. The authors would like to acknowledge the tremendous contribution of all members of the ProtecT study research group, and especially the following who were involved in this research (Prasad Bollina, Sue Bonnington, Lynn Bradshaw, James Catto, Debbie Cooper, Michael Davis, Liz Down, Andrew Doble, Alan Doherty, Garrett Durkan, Emma Elliott, David Gillatt, Pipa Herbert, Peter Holding, Joanne Howson, Mandy Jones, Roger Kockelbergh, Howard Kynaston, Teresa Lennon, Norma Lyons, Hing Leung, Malcolm Mason, Hilary Moody, Philip Powell, Alan Paul, Stephen Prescott, Derek Rosario, Patricia O’Sullivan, Pauline Thompson, Sarah Tidball). They would also like to thank Gemma Marsden, who processed the blood samples at the biorepository. Department of Health disclaimer: The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Department of Health. This work was supported by the World Cancer Research Fund UK (Grant Number 2006/15). RG is recipient of a Cancer Research UK Graduate Training Fellowship (C31211/A10095) and a Cancer Research UK Population Research Postdoctoral Fellowship (C31211/A15194). The UK Department of Health funded the ProtecT study through the NIHR Health Technology Assessment programme. JPK is funded by a Wellcome Trust 4 years PhD studentship in molecular, genetic, and life course epidemiology (WT083431MA). The Integrative Epidemiology Unit is supported by the Medical Research Council and the University of Bristol. The NIHR Bristol Nutrition Biomedical Research Unit is funded by the National Institute for Health Research (NIHR) and is a partnership between University Hospitals Bristol NHS Foundation Trust and the University of Bristol.

Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use,
distribution, and reproduction in any medium, provided the original author(s) and the source are credited.

References

1. Giovannucci E (2005) The epidemiology of vitamin D and cancer incidence and mortality: a review (United States). Cancer Causes Control 16:83–95
2. Lou YR, Qiao S, Talonpoika R, Syvala H, Tuohimaa P (2004) The role of vitamin D3 metabolism in prostate cancer. J Steroid Biochem Mol Biol 92:317–325
3. Willis MS, Wians FH (2003) The role of nutrition in preventing prostate cancer: a review of the proposed mechanism of action of various dietary substances. Clin Chim Acta 330:57–83
4. Lokeshwar BL, Schwartz GG, Selzer MG et al (1999) Inhibition of prostate cancer metastasis in vivo: a comparison of 1,25-Dihydroxyvitamin D (Calcitriol) and EB1089. Cancer Epidemiol Biomark Prev 8:241–248
5. Stewart LV, Weigel NL (2004) Vitamin D and prostate cancer. Exp Biol Med 229:277–284
6. Schwartz GG (2005) Vitamin D and the epidemiology of prostate cancer. Semin Dial 18:276–289
7. Polek TC, Weigel NL (2002) Vitamin D and prostate cancer. J Androl 23:9–17
8. Gilbert R, Metcalfe C, Oliver SE et al (2009) Life course sun exposure and risk of prostate cancer: population-based nested case–control study and meta-analysis. Int J Cancer 125:1414–1423
9. World Cancer Research Fund/American Institute for Cancer Research (2007) Food, nutrition, physical activity, and the prevention of cancer: a global perspective. AICR, Washington
10. Gilbert R, Martin RM, Beynon R et al (2011) Associations of circulating and dietary vitamin D with prostate cancer risk: a systematic review and dose-response meta-analysis. Cancer Causes Control 22(3):319–340
11. Gilbert R, Metcalfe C, Fraser WD et al (2012) Associations of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer 131:1187–1196
12. Gilbert R, Metcalfe C, Fraser WD et al (2012) Associations of circulating retinol, vitamin E and 1,25-dihydroxyvitamin D with prostate cancer diagnosis, stage and grade. Cancer Causes Control 23:1865–1873
13. Davey Smith G (2011) Use of genetic markers and gene-diet interactions for interpreting population-level causal influences of diet on health. Genes Nutr 6:27–43
14. Davey Smith G, Ebrahim S (2003) ‘Mendelian randomization’: can genetic epidemiology contribute to understanding environmental determinants of disease? Int J Epidemiol 32:1–22
15. Cheng JB, Levine MA, Bell NH, Mangelsdorf DJ, Russell DW (2004) Genetic evidence that the human CYP2R1 enzyme is a key vitamin D 25-hydroxylase. Proc Natl Acad Sci USA 101:7711–7715
16. Sakaki T, Kagawa N, Yamamoto K, Inouye K (2005) Metabolism of vitamin D-3 by cytochromes P450. Front Biosci 10:119–134
17. Speckaert M, Huang GM, Delanghe JR, Taes YEC (2006) Biological and clinical aspects of the vitamin D binding protein (Gc-globulin) and its polymorphism. Clin Chim Acta 372:33–42
18. Chen L, Davey Smith G, Evans DM et al (2009) Genetic variants in the vitamin D receptor are associated with advanced prostate cancer at diagnosis: findings from the prostate testing for cancer and treatment study and a systematic review. Cancer Epidemiol Biomark Prev 18:2874–2881
19. Ahn J, Ku Y, Stolzenberg-Solomon R et al (2010) Genome-wide association study of circulating vitamin D levels. Hum Mol Genet 19:2739–2745
20. Wang TJ, Zhang F, Richards JB et al (2010) Common genetic determinants of vitamin D insufficiency: a genome-wide association study. Lancet 376:180–188
21. Lane JA, Hamdy FC, Martin RM, Turner EL, Neal DE, Donovan JL (2010) Latest results from the UK trials evaluating prostate cancer screening and treatment: the CAP and ProtecT studies. Eur J Cancer 46:3095–3101
22. Ma J, Stampfer MJ, Gann PH et al (1998) Vitamin D receptor polymorphisms, circulating vitamin D metabolites, and risk of prostate cancer in United States physicians. Cancer Epidemiol Biomark Prev 7:385–390
23. Ahn J, Albanes D, Berndt SI et al (2009) Vitamin D-related genes, serum vitamin D concentrations and prostate cancer risk. Carcinogenesis 30:769–776
24. Mikhak B, Hunter DJ, Spiegelman D, Platz EA, Hollis BW, Giovannucci E (2007) Vitamin D receptor (VDR) gene polymorphisms and haplotypes, interactions with plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D, and prostate cancer risk. Prostate 67:911–923
25. Ohori M, Wheeler TM, Scardino PT (1994) The New American Joint Committee on Cancer and International Union Against Cancer TNM classification of prostate cancer. Clin Correl Cancer 74:104–114
26. Lewis SJ, Murad A, Chen L et al (2010) Associations between an obesity related genetic variant (FTO rs9939609) and prostate cancer risk. PLoS One 5:e13485
27. Bonilla C, Gilbert R, Kemp JP et al (2013) Using genetic proxies for lifetime sun exposure to assess the causal relationship of sun exposure with circulating vitamin D and prostate cancer risk. Cancer Epidemiol Biomark Prev 22:597–606
28. Fraser WD, Durham BH, Berry JL, Mawer EB (1997) Measurement of plasma 1,25 dihydroxyvitamin D using a novel immunoextraction technique and immunoassay with iodine labelled vitamin D tracer. Ann Clin Biochem 34:632–637
29. Berry D, Vimalaswaran K, Whitaker J, Hingorani A, Hyppönen E (2012) Evaluation of genetic markers as instruments for Mendelian randomization studies on vitamin D. PLoS One 7:e37465
30. Palmer TM, Lawlor DA, Harbord RM et al (2011) Using multiple genetic variants as instrumental variables for modifiable risk factors. Stat Methods Med Res 21:223–242
31. Rowlands MA, Holly JM, Gunnell D et al (2010) The relation between adiposity throughout the life course and variation in IGFs and IGFBPs: evidence from the ProtecT (prostate testing for cancer and treatment) study. Cancer Causes Control 21:1829–1842
32. Janssen KJM, Donders AR, Harrell FE Jr et al (2010) Missing data and treatment) study. Cancer Causes Control 21:1829–1842
33. Bonilla C, Gilbert R, Kemp JP et al (2013) Using genetic proxies for lifetime sun exposure to assess the causal relationship of sun exposure with circulating vitamin D and prostate cancer risk. Cancer Epidemiol Biomark Prev 22:597–606
34. Thompson IM, Ankerst DP, Chi C et al (2005) Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/mL or lower. JAMA: J Am Med Assoc 294:66–70
35. Hernandez-Diaz S, Robins JM (2004) A structural approach to selection bias. Epidemiology 15:615–625. doi: 10.1097/01.ede.0000135714.63482.43
36. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D (2006) Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 38:904–909
37. Shui IM, Mucci LA, Kraft P et al (2012) Vitamin D-related genetic Variation, plasma vitamin D, and risk of lethal prostate cancer: a global perspective. AICR, Washington
38. Mondul AM, Shui IM, Yu K et al (2013) Genetic variation in the vitamin D pathway in relation to risk of prostate cancer—results from the breast and prostate cancer cohort consortium. Cancer Epidemiol Biomark Prev 22:688–696
39. Xu Y, Shibata A, McNeal JE, Stamey TA, Feldman D, Peehl DM (2003) Vitamin D receptor start codon polymorphism (FokI) and prostate cancer progression. Cancer Epidemiol Biomark Prev 12:23–27
40. Guo Z, Wen J, Kan Q et al (2013) Lack of association between vitamin D receptor gene FokI and BsmI polymorphisms and prostate cancer risk: an updated meta-analysis involving 21,756 subjects. Tumor Biol 34:3189–3200
41. Holt SK, Kwon EM, Koopmeiners JS et al (2010) Vitamin D pathway gene variants and prostate cancer prognosis. Prostate 70:1448–1460
42. Gilbert R, Metcalfe C, Fraser WD et al (2013) Associations of circulating 25-hydroxyvitamin-D, 1,25-dihydroxyvitamin-D and vitamin D-pathway genes with prostate-specific antigen progression in men with localized prostate cancer undergoing active monitoring. Eur J Cancer Prev 22:121–125
43. Peehl DM, Feldman D (2003) The role of vitamin D and retinoids in controlling prostate cancer progression. Endocr Relat Cancer 10:131–140
44. Barreto AM, Schwartz GG, Woodruff R, Cramer SD (2000) 25-Hydroxyvitamin D3, the prohormone of 1,25-Dihydroxyvitamin D3, inhibits the proliferation of primary prostatic epithelial cells. Cancer Epidemiol Biomark Prev 9:265–270
45. Stewart LV, Weigel NL (2004) Vitamin D and prostate cancer. Exp Biol Med 229:277–284
46. Tuohimaa P, Golovko O, Kalueff A et al (2005) Calcidiol and prostate cancer. J Steroid Biochem Mol Biol 93:183–190
47. Weinstein SJ, Mondul AM, Kopp W, Rager H, Virtamo J, Albanes D (2013) Circulating 25-hydroxyvitamin D, vitamin D-binding protein and risk of prostate cancer. Int J Cancer 132:2940–2947
48. Gilbert R, Martin RM, Donovan J et al. (2014) Misclassification of outcome in case–control studies: methods for sensitivity analysis. Stat Methods Med Res
49. Epstein M, Andre´n O, Kasperzyk J et al (2012) Seasonal variation in expression of markers in the vitamin D pathway in prostate tissue. Cancer Causes Control 23:1359–1366
50. Chun RF, Peercy BE, Adams JS, Hewison M (2012) Vitamin D binding protein and monocyte response to 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D: analysis by mathematical modeling. PLoS One 7(1):e30773
51. Cancer Research UK. (2014) CancerStats report prostate cancer—UK, Cancer Research UK. http://info.cancerresearchuk.org/cancerstats/types/prostate